To direct the Secretary of Labor to issue an occupational safety and health standard that requires employers to keep opioid overdose reversal drugs onsite and develop and implement training plans to respond to drug overdose emergencies and to amend the Omnibus Crime Control and Safe Streets Act of 1968 to expand the grants authorized under the Comprehensive Opioid Abuse Grant Program.
About This Bill
Committee
Latest Action · November 6, 2023
Referred to the Committee on Education and the Workforce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The Overdose Reversal Medication Act directs the Secretary of Labor to create workplace safety standards requiring most employers to keep opioid overdose reversal medications like naloxone on site and train employees to recognize overdose emergencies and administer these drugs. The law requires an interim standard within one year of enactment and a final standard within two years, with the number of doses required based on workplace size, type of occupation, and overdose risk assessment. The bill also expands a federal grant program to help businesses, nonprofits, and community organizations train employees and acquire overdose reversal medications, with priority given to states that have good samaritan laws protecting people who administer these drugs in emergencies. The legislation affects all types of employers across the country and applies to opioid overdose reversal drugs approved by the Food and Drug Administration. While no specific funding amount is mentioned in the text, the bill authorizes expanded grants under the existing Comprehensive Opioid Abuse Grant Program to support training and medication acquisition efforts.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.